Home » Stocks » MTCR

Metacrine, Inc. (MTCR)

Stock Price: $8.44 USD -0.42 (-4.74%)
Updated Feb 25, 2021 4:00 PM EST - Market closed
Market Cap 221.67M
Revenue (ttm) 2.18M
Net Income (ttm) n/a
Shares Out 6.44M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 25
Last Price $8.44
Previous Close $8.86
Change ($) -0.42
Change (%) -4.74%
Day's Open 8.82
Day's Range 8.38 - 8.93
Day's Volume 18,755
52-Week Range 7.64 - 16.19

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GuruFocus - 1 week ago

There are some investors who purchase stocks that are trading below their liquidation value because they believe they can make impressive gains out of their investments after the market has re...

Other stocks mentioned: ABIO, ATHA
GlobeNewsWire - 1 week ago

Publication highlights the first clinical evidence that the risk-benefit profile of FXR agonists can be enhanced through structural optimization Publication highlights the first clinical evide...

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patie...

GlobeNewsWire - 1 month ago

Trial Designed to Evaluate Potential of FXR-Based Combination Therapy in a Growing Segment of NASH Patient Population with Significant Unmet Needs Trial Designed to Evaluate Potential of FXR-B...

GlobeNewsWire - 2 months ago

MET642 Demonstrated Sustained Pharmacokinetic Profile and Robust FXR Target Engagement with Once-Daily Oral Dosing, without Pruritis or LDL-Cholesterol Increase

GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patie...

GlobeNewsWire - 3 months ago

Upcoming Data at AASLD Support Robust, Sustained FXR Activation by MET409 in Patients with NASH

GlobeNewsWire - 4 months ago

New Data Support Robust, Sustained FXR Activation by MET409 in Patients with NASH and Demonstrate Predictability of Liver Fat Reductions as Early as Week 4 of Treatment New Data Support Robust...

InvestorPlace - 5 months ago

Did you miss the Metacrine IPO? No worries.

Market Watch - 5 months ago

Shares of Metacrine Inc. got a bullish start to their public life, as they opened 10.7% their initial public offering price.

About MTCR

Metacrine, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases in the United States. It is developing MET409, a therapy that is in a Phase Ib proof-of-concept clinical trial for the treatment of non-alcoholic steatohepatitis patients; and MET642, a candidate, which is in Phase 1 clinical trial for the treatment of non-alcoholic steatohepatitis patients. The company has a research collaboration with Novo Nordisk A/S to perform research activities relate... [Read more...]

Industry
Biotechnology
IPO Date
Sep 16, 2020
Stock Exchange
NASDAQ
Ticker Symbol
MTCR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Metacrine stock is "Strong Buy." The 12-month stock price forecast is 20.50, which is an increase of 142.89% from the latest price.

Price Target
$20.50
(142.89% upside)
Analyst Consensus: Strong Buy